PT-141 10mg
Description:
Bremelanotide (or PT-141) is a compound developed for the treatment of female sexual dysfunction, hemorrhagic shock, and reperfusion injury. It works by activating melanocortin MC1R and MC4R receptors, modulating inflammation and limiting ischemia. Initially, the drug was studied for intranasal use in the treatment of female sexual dysfunction, but in 2008 development of the drug for this use was temporarily discontinued after reports of adverse side effects associated with increased blood pressure. In March 2012, Palatin Technologies was conducting a phase 2B study in humans using subcutaneous injection of the drug, which the manufacturer claims has a very small effect on blood pressure.
Bremelanotide was developed from the peptide hormone Melanotan 2, which has been investigated as a tanning agent without sun exposure. Melanotan 2 has been shown in initial tests to induce sexual arousal and spontaneous erections, in addition to tanning. Bremelanotide has been shown in studies to be effective in treating sexual dysfunction in both men (erectile dysfunction) and women (sexual arousal disorder). Unlike Viagra and other related medications, bremelanotide does not affect the vascular system, but increases desire directly through its effect on the nervous system.
Objective of using
Used for male or female sexual dysfunction.
Mechanism of action
Bremelanotide is an alpha-melanocyte-stimulating hormone (alpha-MSH) analogue that activates MC3-R and MC4-R melanocortin receptors in the central nervous system. Due to its centrally mediated activity, bremelanotide has potential for the treatment of erectile dysfunction, as well as for possible use in unmet medical needs associated with decreased sexual motivation and loss of libido.
PT-14 is a powerful erection initiator with minimal side effects, a rapid onset of action, and a fairly long duration of action. Notably, recent phase II studies confirm that erectile responses are enhanced with sexual stimulation. Due to its central mechanism of action, PT-141 can act independently or synergistically with PDE-5 inhibitors (Viagra, Cialis) and provide a useful alternative therapy for erectile dysfunction of organic and psychogenic origin. A randomized, prospective, placebo-controlled study compared the treatment of ED with intranasal Sildenafil 141 mg intranasal PT-141. The combined use of the two medications led to a significant increase in time to base rigidity (>60%) compared to the use of Sildenafil alone during a 2.5-hour monitoring session. The combination of medications was well tolerated, with no significant increase in side effects compared to Sildenafil PT-141 alone.
Effects:
The erectogenic potential of PT-, its tolerability profile, and its ability to induce significant erections in patients who do not respond adequately to a PDE inhibitor (Syslais, Viagra) suggest that PT- may provide an alternative treatment.
Increased sexual desire and erection.
Side effects
Nausea,
Flushing
, Headache.
How to use:
The first erection occurs in about 30 minutes. The peak concentration of the substance in the blood drops 60 minutes after injection and gradually decreases over 4 hours.
Combination with other drugs:
For a better effect, it can be used with medications such as Sildenafil and Tadalafil.
How to prepare a solution
: To prepare an injectable solution, take a syringe that already contains a diluent and inject it into an injectable vial containing a lyophilized powder. Tilt the vial so that the needle touches the wall of the vial. Avoid injecting the diluent directly into the lyophilized powder. The solvent should flow slowly down the wall of the vial (do not fill it all at once and do not rush). After all the diluent has been added to the peptide vial, mix gently (but do not shake or agitate the vial) until the lyophilized powder dissolves and you are left with a clear liquid. Now the medication is ready for use.
Never mix one peptide with another in the same syringe. This creates a risk of destroying fragile peptide molecules.
Dosage and Administration
Initial dosage
The recommended starting dose is 0.5 mg. This initial dose allows the body to acclimate to the peptides and assess the individual response. It is advisable to administer the initial dose under medical supervision to monitor for possible reactions.
Maintenance dosage
Following the initial dose, the maintenance dosage of PT-141 is typically between 1 and 2 mg. This dosage can be administered as needed, based on individual response and desired effect. It is important to follow the recommended dosing frequency provided by your healthcare professional.
The injection
can be subcutaneous or intramuscular, depending on personal preference.
Store
The resulting solution can be stored for approximately 21 days in the refrigerator at a temperature of 2 to 8 degrees Celsius. The storage time increases if the solution is prepared with bacteriostatic water.
Description:
Bremelanotide (or PT-141) is a compound developed for the treatment of female sexual dysfunction, hemorrhagic shock, and reperfusion injury. It works by activating melanocortin MC1R and MC4R receptors, modulating inflammation and limiting ischemia. Initially, the drug was studied for intranasal use in the treatment of female sexual dysfunction, but in 2008 development of the drug for this use was temporarily discontinued after reports of adverse side effects associated with increased blood pressure. In March 2012, Palatin Technologies was conducting a phase 2B study in humans using subcutaneous injection of the drug, which the manufacturer claims has a very small effect on blood pressure.
Bremelanotide was developed from the peptide hormone Melanotan 2, which has been investigated as a tanning agent without sun exposure. Melanotan 2 has been shown in initial tests to induce sexual arousal and spontaneous erections, in addition to tanning. Bremelanotide has been shown in studies to be effective in treating sexual dysfunction in both men (erectile dysfunction) and women (sexual arousal disorder). Unlike Viagra and other related medications, bremelanotide does not affect the vascular system, but increases desire directly through its effect on the nervous system.
Objective of using
Used for male or female sexual dysfunction.
Mechanism of action
Bremelanotide is an alpha-melanocyte-stimulating hormone (alpha-MSH) analogue that activates MC3-R and MC4-R melanocortin receptors in the central nervous system. Due to its centrally mediated activity, bremelanotide has potential for the treatment of erectile dysfunction, as well as for possible use in unmet medical needs associated with decreased sexual motivation and loss of libido.
PT-14 is a powerful erection initiator with minimal side effects, a rapid onset of action, and a fairly long duration of action. Notably, recent phase II studies confirm that erectile responses are enhanced with sexual stimulation. Due to its central mechanism of action, PT-141 can act independently or synergistically with PDE-5 inhibitors (Viagra, Cialis) and provide a useful alternative therapy for erectile dysfunction of organic and psychogenic origin. A randomized, prospective, placebo-controlled study compared the treatment of ED with intranasal Sildenafil 141 mg intranasal PT-141. The combined use of the two medications led to a significant increase in time to base rigidity (>60%) compared to the use of Sildenafil alone during a 2.5-hour monitoring session. The combination of medications was well tolerated, with no significant increase in side effects compared to Sildenafil PT-141 alone.
Effects:
The erectogenic potential of PT-, its tolerability profile, and its ability to induce significant erections in patients who do not respond adequately to a PDE inhibitor (Syslais, Viagra) suggest that PT- may provide an alternative treatment.
Increased sexual desire and erection.
Side effects
Nausea,
Flushing
, Headache.
How to use:
The first erection occurs in about 30 minutes. The peak concentration of the substance in the blood drops 60 minutes after injection and gradually decreases over 4 hours.
Combination with other drugs:
For a better effect, it can be used with medications such as Sildenafil and Tadalafil.
How to prepare a solution
: To prepare an injectable solution, take a syringe that already contains a diluent and inject it into an injectable vial containing a lyophilized powder. Tilt the vial so that the needle touches the wall of the vial. Avoid injecting the diluent directly into the lyophilized powder. The solvent should flow slowly down the wall of the vial (do not fill it all at once and do not rush). After all the diluent has been added to the peptide vial, mix gently (but do not shake or agitate the vial) until the lyophilized powder dissolves and you are left with a clear liquid. Now the medication is ready for use.
Never mix one peptide with another in the same syringe. This creates a risk of destroying fragile peptide molecules.
Dosage and Administration
Initial dosage
The recommended starting dose is 0.5 mg. This initial dose allows the body to acclimate to the peptides and assess the individual response. It is advisable to administer the initial dose under medical supervision to monitor for possible reactions.
Maintenance dosage
Following the initial dose, the maintenance dosage of PT-141 is typically between 1 and 2 mg. This dosage can be administered as needed, based on individual response and desired effect. It is important to follow the recommended dosing frequency provided by your healthcare professional.
The injection
can be subcutaneous or intramuscular, depending on personal preference.
Store
The resulting solution can be stored for approximately 21 days in the refrigerator at a temperature of 2 to 8 degrees Celsius. The storage time increases if the solution is prepared with bacteriostatic water.